Magnetic nanomedicine for tumor suppression and therapy
a nanomedicine and tumor technology, applied in the field of magnetic nanomedicine for tumor suppression and therapy, can solve the problems of limited encapsulation rate, limited dosage applied and therapy effectiveness, serious side effects on other organs of the human body, etc., to improve the thermal stability, increase the local medicine concentration, and great economic advantage
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
embodiment 1
Method of Preparing Magnetic Nanoparticles (MNPs) of Magnetic Nanomedicine of the Present Invention
[0037]Preparation of MNPs: utilize a co-deposition method to prepare magnetic nanoparticles Fe3O4 (MNPs)
[0038]Firstly, add 0.7 gram of FeCl3 (concentration 4.32×10−3 mole), 1.07 gram of FeCl2.4H2O (concentration 6.48×10−3 mole), and 400 mL of double distilled water into a three-neck bottle, and stir it with a magnet in a nitrogen environment for 5 minutes, so as to make FeCl3 and FeCl2.4H2O fully dissolve into water; then add 20 mL NaOH aqueous solution of concentration 0.864 N into the three-neck bottle, and then heat it to a temperature of 80° C. to produce an aqueous solution containing MNPs.
[0039]Separating MNPs: after cooling down the aqueous solution containing MNPs, agitate it in an ultrasonic agitator to make the MNPs distributed uniformly in the aqueous solution; then pour the aqueous solution containing MNPs into a separating funnel, and place a strong magnet outside the funn...
embodiment 2
Method of Producing a SPAnH / MNPs Magnetic Nanocomposite
[0042]Firstly, mix 2 mL of MNPs aqueous solution having concentration of 10 mg / mL, and 0.5 mL of SPAnNa (poly[aniline-co-sodium N-(1-one-butyric acid)aniline]) aqueous solution having concentration of 4.9 mg / mL uniformly into a mix solution, and put this mixed solution into an ultrasonic agitator to make its contents mix uniformly, then drop in HCl of concentration of 0.5 M. In an acidic environment, SPAnNa aggregates to form SPAnH, and the SPAnH envolops MNPs to form a e SPAnH / MNPs magnetic nanocomposite with the core being MNPs, and with the shell being SPAnH. Next, separate the SPAnH / MNPs magnetic nanocomposite from the solution, and disperse it in double distilled water, hereby forming a SPAnH / MNPs magnetic nanocomposite in aqueous solution.
[0043]The observation result of SPAnH / MNPs magnetic nanocomposite using a transmission electronic microscope is as shown in FIG. 1(A), wherein it shows that the diameter of SPAnH / MNPs mag...
embodiment 3
Efficiency of Preparing EPI / SPAnH / MNPs Magnetic Nanomedicine by Making Epirubicin (EPI) of Various Concentrations to React with SPAnH / MNPs Magnetic Nanocomposite, and the Maximum Medicine Bonding Efficiency
[0046]Dissolve 24 mg of EDC (1-ethyl-3-3-(dimethylaminepropyl)carbodiimidehydro chloride) and 27 mg of sulfo-NHS (N-hydroxysulfosuccinimide sodium salt) in 0.5 M MES buffer (2-Morpholinoethanesulfonic acid, pH=6.3) to form a mixed reaction solution. Next, take 0.2 mL of the mixed reaction solution to react with 0.2 mL of SPAnH / MNPs magnetic nanocomposite solution for 30 minutes, and then flush the product with the MES buffer. Then, add 30 μg, 120 μg, 360 μg, or 560 μg of Epirubicin (EPI) medicine and perform medicine bonding reaction in temperature 20 to 25° C., to form EPI / SPAnH / MNPs magnetic nanomedicine, with its structure as shown in FIG. 9. Subsequently, flush off free EPI several times with de-ionized water. Then, determine the quantity of the flushed-off free EPI with HPLC ...
PUM
| Property | Measurement | Unit |
|---|---|---|
| diameter | aaaaa | aaaaa |
| particle diameter | aaaaa | aaaaa |
| temperature | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 


